MedPath

Effects of anamorelin on microbiota

Not Applicable
Conditions
Cancer cachexia
Registration Number
JPRN-UMIN000047574
Lead Sponsor
Cancer Treament Center, Kansai Medical University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with a prognosis of 12 weeks or less Previous anamorelin administration Patients with concomitant severe cardiac disease Hepatic dysfunction (Child-Pugh B or C) Difficulty with oral intake due to organic abnormalities (e.g. obstruction) of the gastrointestinal tract Other patients who are deemed inappropriate by the principal investigator

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in the diversity of intestinal microbiota before and after anamorelin administration
Secondary Outcome Measures
NameTimeMethod
Change in body weight Percent change in EORTC-QLQ-C15PAL score Percent change in appetite-related items in EORTC-QLQ-C15PAL score
© Copyright 2025. All Rights Reserved by MedPath